A Feasibility Study of MRI and PET Imaging to Assess Response to MK-3475 (Pembrolizumab) in Patients with Metastatic Melanoma

Protocol: 
AAAO2558
Phase: 
Feasibility

A Feasibility Study of MRI and PET Imaging to Assess Response to MK-3475 (Pembrolizumab) in Patients with Metastatic Melanoma

Are you Eligible? (Inclusion Criteria)

Participants must have stage III or Stage IV measurable metastatic melanoma.

Specialty Area(s)

Immunotherapy

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States